These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 12621737

  • 21. [Antibacterial kinetics of fosfomycin (author's transl)].
    Gevaudan MJ, Mallet MN, Charrel J, Dalmas N, Gulian C, Gevaudan P.
    Ann Biol Clin (Paris); 1979; 37(6):327-30. PubMed ID: 547759
    [Abstract] [Full Text] [Related]

  • 22. [Bacteriological studies on fosfomycin. Antibacterial activity in vitro and in vivo (author's transl)].
    Miyauchi K, Yoshida T, Kasai T, Saito T, Hirano H.
    Jpn J Antibiot; 1975 Jun; 28(3):320-30. PubMed ID: 807758
    [Abstract] [Full Text] [Related]

  • 23. [Conditions influencing the activity of fosfomycin in vitro (author's transl)].
    Haag R, Vömel W.
    Immun Infekt; 1979 Dec; 7(6):202-9. PubMed ID: 396228
    [Abstract] [Full Text] [Related]

  • 24. Activity of fosfomycin when tested against US contemporary bacterial isolates.
    Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D.
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):143-146. PubMed ID: 30236530
    [Abstract] [Full Text] [Related]

  • 25. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V.
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [Abstract] [Full Text] [Related]

  • 26. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y, Hirose T, Tanaka N, Hikichi Y, Shigeta S, Shiraiwa Y, Kameoka H, Yoshida H, Ogata M, Tazaki H.
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [Abstract] [Full Text] [Related]

  • 27. An improved susceptibility test based on Amberlite reveals the potential antilisterial activity of fosfomycin in vitro.
    Han L, Lei J, Han S, He L, Ma C, Yu P, Wu X, Xu J.
    Can J Microbiol; 2013 Apr; 59(4):252-9. PubMed ID: 23586749
    [Abstract] [Full Text] [Related]

  • 28. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro.
    Kobayashi Y, Sumitani Y, Sugita K, Aikawa N.
    Int J Antimicrob Agents; 2007 Dec; 30(6):563-4. PubMed ID: 17900870
    [No Abstract] [Full Text] [Related]

  • 29. Practical agar-based disk potentiation test for detection of fosfomycin-nonsusceptible Escherichia coli clinical isolates producing glutathione S-transferases.
    Nakamura G, Wachino J, Sato N, Kimura K, Yamada K, Jin W, Shibayama K, Yagi T, Kawamura K, Arakawa Y.
    J Clin Microbiol; 2014 Sep; 52(9):3175-9. PubMed ID: 24951800
    [Abstract] [Full Text] [Related]

  • 30. [Antibacterial activities and electron microscopic studies of imipenem in combination with fosfomycin against methicillin and fosfomycin resistant strains of Staphylococcus aureus].
    Saionji K, Shitara S, Kobayashi I.
    Jpn J Antibiot; 1990 Mar; 43(3):379-87. PubMed ID: 2374289
    [Abstract] [Full Text] [Related]

  • 31. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA, Trujillano Martín I, Baquero F, Cisterna R, Gobernado M, Liñares F, Martín-Luengo F, Piédrola G.
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [Abstract] [Full Text] [Related]

  • 32. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Drugs Exp Clin Res; 1992 Dec; 18(8):311-7. PubMed ID: 1338041
    [Abstract] [Full Text] [Related]

  • 33. [Fosfomycin susceptibility of clinical isolates from otorhinolaryngological infections].
    Deguchi K.
    Jpn J Antibiot; 1983 Oct; 36(10):2844-8. PubMed ID: 6674519
    [Abstract] [Full Text] [Related]

  • 34. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR.
    J Antimicrob Chemother; 2009 Oct; 64(4):829-36. PubMed ID: 19679597
    [Abstract] [Full Text] [Related]

  • 35. Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.
    Tariq TM.
    J Coll Physicians Surg Pak; 2014 Jun; 24(6):396-399. PubMed ID: 24953929
    [Abstract] [Full Text] [Related]

  • 36. [Investigations on the antibacterial activity of fosfomycin on DST-agar (author's transl)].
    Hirschl A, Rotter M, Maruna H.
    Zentralbl Bakteriol Orig A; 1978 Dec; 242(4):537-46. PubMed ID: 749420
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin.
    Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Kapaskelis A, Samonis G.
    Int J Antimicrob Agents; 2010 May; 35(5):497-9. PubMed ID: 20226634
    [Abstract] [Full Text] [Related]

  • 38. Fosfomycin, antimicrobial activity in vitro and in vivo.
    Goto S.
    Chemotherapy; 1977 May; 23 Suppl 1():63-74. PubMed ID: 401721
    [Abstract] [Full Text] [Related]

  • 39. [Fosfomycin resistance in Staphylococcus saprophyticus and other species of coagulase-negative staphylococci].
    Loulergue J, Pinon G, Laudat P, Audurier A.
    Ann Microbiol (Paris); 1984 May; 135A(2):239-47. PubMed ID: 6721325
    [Abstract] [Full Text] [Related]

  • 40. [Comparison of susceptibilities for fosfomycin determined by various methods in clinical isolates in 2003 -2004].
    Muramatsu H, Ishikawa J, Nagura O, Horii T.
    Jpn J Antibiot; 2007 Apr; 60(2):107-24. PubMed ID: 17612258
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.